## UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION OFFICE OF ADMINISTRATIVE LAW JUDGES



	, Uni <b>gi</b>
In the Matter of	)
Otto Bock HealthCare North America, Inc.,	) Docket No. 9378
a corporation,	) )
Respondent.	) )

## ORDER ON RESPONDENT'S MOTION FOR IN CAMERA TREATMENT OF CERTAIN TRIAL EXHIBITS

Pursuant to Rule 3.45(b) of the Commission's Rules of Practice, on September 14, 2018, Respondent Otto Bock HealthCare North America, Inc. ("Ottobock") filed an unopposed motion for *in camera* treatment for three trial exhibits that were admitted into evidence on September 13, 2018 ("September 14 Motion"). Respondent represents that Federal Trade Commission ("FTC" or "Commission") Complaint Counsel does not oppose the request.

The July 2, 2018 Order on Respondent's initial motion for *in camera* treatment sets forth the standards for *in camera* treatment by which the September 14 Motion is evaluated. Respondent describes in detail the confidential nature of the exhibits, the competitive harm that Ottobock would suffer if the exhibits were made publicly available, and the measures that Ottobock takes to ensure that the information contained in these exhibits remains confidential.

Respondent has met its burden of showing that the three exhibits meet the standard for *in camera* treatment. *In camera* treatment for a period of ten years to expire on July 1, 2028 is GRANTED for: RX1098, RX1099, and RX1100.

ORDERED:

D. Michael Chappell

Chief Administrative Law Judge

Date: September 17, 2018